You have access
A Phase II Trial of Two Durations of Bevacizumab Added to Neoadjuvant Gemcitabine for Borderline and Locally Advanced Pancreatic Cancer
KLAUS SAHORA, MARTIN SCHINDL, IRENE KUEHRER, AXEL EISENHUT, GREGOR WERBA, CHRISTINE BROSTJAN, BELA TELEK, AHMED BA'SSALAMAH, JUDITH STIFT, SEBASTIAN F. SCHOPPMANN and MICHAEL GNANT
Anticancer Research May 2014, 34 (5) 2377-2384;